Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but ...

We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...

Humira (adalimumab) has dominated in the inflammatory diseases including psoriasis and rheumatoid arthritis markets for a decade, and AbbVie needs newer drugs that outperform it and rivals in each ...

with the latter two rivalling Humira in indications such as rheumatoid arthritis and psoriasis. Kavya Gopal, head of specialty at Sandoz UK, said: “Biosimilars offer the NHS the potential to ...

Psoriasis is usually treated with a combination of self-care interventions, medications, and ultraviolet (UV) light therapy. While there is no cure for psoriasis, it can be treated effectively ...

Nov. 12, 2024 — Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other ...

Investors looking for a way to pump up their passive income streams want to turn their attention toward the pharmaceutical ...

The Manufacturers Life Insurance Company lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 1.8% ...

Algert Global LLC purchased a new stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) in the 3rd quarter, according to ...

After hours: November 29 at 4:56 PM EST Loading Chart for ABBV ...